2024-03-28T15:50:50Zhttp://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/86012021-06-23T09:48:45Zcom_10324_1133com_10324_931com_10324_894col_10324_1209
2015-03-04T08:56:22Z
urn:hdl:10324/8601
Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study
Martín Arias, Luis Hermenegildo
Treceño Lobato, Carlos
García Ortega, María Pilar
Rodríguez Paredes, Juan
Escudero, Antonio
Sáinz Gil, María
Salado Valdivieso, María Inés
Velasco González, Verónica
Carvajal García-Pando, Alfonso
Osteoporosis - Tratamiento farmacológico
Producción Científica
Introduction Bisphosphonates are used worldwide to treat
osteoporosis and, thus, to prevent fractures. Though they
have been proven in clinical trials to avoid some fractures,
their effectiveness in reducing hip fractures is unclear. The
aim of the present study was to explore the relationship
between bisphosphonate use and hip fracture trends in
Spain.
Methods For this purpose, an ecologic study spanning 2002
to 2008 was conducted in Spain. Consumption data were
obtained from the Spanish Ministry of Health and Social
Policy. The number of hip fractures was obtained from
hospital discharges; annual hip fracture rates were determined
and standardized using the Spanish 2002 population
census. A linear regression was performed between fracture
rate and use of bisphosphonates; R2 and Pearson correlation
coefficient were calculated.
Results From 2002 to 2008, dispensed prescriptions of
bisphosphonates in Spain increased from 3.28 to 17.66
DDD/1,000 inhabitants per day. In the same period, the
crude hip fracture rate increased from 2.85 to 3.02 cases
per 1,000 inhabitants older than 50 years; however, when
age standardized rates were estimated, the rate declined
from 2.85 to 2.79. Analyzed by sex, the standardized rate
for men slightly increased from 1.45 to 1.48, while for
women the rate significantly dropped from 4.00 to 3.91.Conclusion A small effect of bisphosphonates on hip fracture
rates can not be ruled out; however, other factors might
partially explain this decline. Assuming this medication was
the only cause for hip fracture rate reduction, the elevated
medication cost to avoid a single hip fracture makes it
necessary to explore less expensive interventions
2015-03-04T08:56:22Z
2015-03-04T08:56:22Z
2013
info:eu-repo/semantics/article
European journal of clinical pharmacology, 2013, vol. 69, no 3, p. 559-564.
0031-6970
http://uvadoc.uva.es/handle/10324/8601
10.1007/s00228-012-1337-z
559
3
564
European journal of clinical pharmacology
69
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Springer Verlag